Naftopidil
From Wikipedia, the free encyclopedia
 |
|
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration |
Oral |
| ATC code | none |
| Legal status | |
| Legal status |
|
| Identifiers | |
|
|
| CAS Number | 57149-07-2  |
| PubChem (CID) | 4418 |
| ChemSpider | 4265  |
| UNII | R9PHW59SFN |
| ECHA InfoCard | 100.220.557 |
| Chemical and physical data | |
| Formula | C24H28N2O3 |
| Molar mass | 392.49 g/mol |
| 3D model (Jmol) | Interactive image |
|
|
|
|
| (what is this?) (verify) |
|
Naftopidil (INN, marketed under the brand name Flivas) is a drug used in benign prostatic hypertrophy which acts as a selective α1-adrenergic receptor antagonist or alpha blocker.[1]
See also[edit]
References[edit]
- ^ Sakai H, Igawa T, Onita T, Furukawa M, Hakariya T, Hayashi M, Matsuya F, Shida Y, Nishimura N, Yogi Y, Tsurusaki T, Takehara K, Nomata K, Shiraishi K, Shono T, Aoki D, Kanetake H (2011). "Efficacy of naftopidil in patients with overactive bladder associated with benign prostatic hyperplasia: prospective randomized controlled study to compare differences in efficacy between morning and evening medication". Hinyokika Kiyo. 57 (1): 7–13. PMID 21304253.
 |
This antihypertensive-related article is a stub. You can help Wikipedia by expanding it. |
